Structure Therapeutics Inc. Operating Cash Flow
Structure Therapeutics Inc. (GPCR) reported Operating Cash Flow of -$104.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Structure Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$120.11M.
- Structure Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $15.23M.
- Structure Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$64.42M.
- Structure Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$51.00M.
- Structure Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$222.20M.
- Structure Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$116.64M.
- Structure Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$79.49M.
- Structure Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$46.12M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$120.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$104.88M 10-Q · filed 2026-08-06 | -$169.30M derived: sum of 3 quarters · filed 2026-08-06 | -$220.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.23M 10-Q · filed 2026-05-07 | -$49.18M derived: sum of 2 quarters · filed 2026-05-07 | -$100.18M derived: sum of 3 quarters · filed 2026-05-07 | -$154.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$64.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$115.41M derived: sum of 2 quarters · filed 2026-02-26 | -$169.97M derived: sum of 3 quarters · filed 2026-08-06 | -$222.20M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$51.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$105.55M derived: sum of 2 quarters · filed 2026-08-06 | -$157.78M 10-Q · filed 2025-11-06 | -$194.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$54.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$106.79M 10-Q · filed 2026-08-06 | -$143.25M derived: sum of 3 quarters · filed 2026-08-06 | -$162.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$52.23M 10-Q · filed 2026-05-07 | -$88.70M derived: sum of 2 quarters · filed 2026-05-07 | -$108.39M derived: sum of 3 quarters · filed 2026-05-07 | -$134.78M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$36.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$56.16M derived: sum of 2 quarters · filed 2026-02-26 | -$82.56M derived: sum of 3 quarters · filed 2026-02-26 | -$116.64M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$19.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$46.09M derived: sum of 2 quarters · filed 2025-11-06 | -$80.17M 10-Q · filed 2025-11-06 | -$101.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$26.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$60.47M 10-Q · filed 2025-08-06 | -$82.20M derived: sum of 3 quarters · filed 2026-02-26 | -$102.76M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$34.08M 10-Q · filed 2025-05-08 | -$55.81M derived: sum of 2 quarters · filed 2026-02-26 | -$76.37M derived: sum of 3 quarters · filed 2026-02-26 | -$93.26M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$21.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$42.29M derived: sum of 2 quarters · filed 2026-02-26 | -$59.18M derived: sum of 3 quarters · filed 2026-02-26 | -$79.49M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$20.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$37.45M derived: sum of 2 quarters · filed 2024-11-13 | -$57.76M 10-Q · filed 2024-11-13 | -$69.78M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$16.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$37.20M 10-Q · filed 2024-08-08 | -$49.23M derived: sum of 3 quarters · filed 2024-08-08 | -$59.71M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$20.31M 10-Q · filed 2024-05-09 | -$32.33M derived: sum of 2 quarters · filed 2024-05-09 | -$42.81M derived: sum of 3 quarters · filed 2024-05-09 | -$52.91M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$12.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$22.51M derived: sum of 2 quarters · filed 2024-03-08 | -$32.60M derived: sum of 3 quarters · filed 2024-03-08 | -$46.12M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$10.48M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | -$20.58M derived: sum of 2 quarters · filed 2023-11-17 | -$34.09M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | -$10.10M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | -$23.61M 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | -$13.52M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |